Qiagen (QGEN) Financial Analysis & Valuation | Quarter Chart
Qiagen (QGEN)
QGENPrice: $40.6
Fair Value: 🔒
🔒score
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for geno... more
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular in... more
Description
Shares
| Market Cap | $8.36B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | NL | CEO | Thierry Bernard |
| IPO Date | 1996-06-28 | CAGR | 0.15% |
| Employees | 5,700 | Website | www.qiagen.com |
| Div. Yield | 0.02% | Payout Ratio | — |
| Buy Back Yield | 0.02% | Total Yield | 0.04% |
QGEN chart loading...
Fundamentals
Technicals
| Enterprise Value | $8.61B | P/E Ratio | 19.9 |
| Forward P/E | 12.35 | PEG Ratio | -0.7 |
| P/S Ratio | 10775.57 | P/B Ratio | 6380.54 |
| P/CF Ratio | 33111.44 | P/FCF Ratio | 45033.95 |
| EPS | $2.04 | EPS Growth 1Y | 353.66% |
| EPS Growth 3Y | -7.46% | EPS Growth 5Y | 129.63% |
| Revenue Growth 1Y | 5.32% | Gross Margin | 0.63% |
| Operating Margin | 0.23% | Profit Margin | 0.2% |
| ROE | 0.12% | ROA | 0.07% |
| ROCE | 0.1% | Current Ratio | 1.61 |
| Quick Ratio | 1.35 | Cash Ratio | 0.65 |
| Debt/Equity | 0.41 | Interest Coverage | 27.24 |
| Altman Z Score | 3.55 | Piotroski Score | 7 |